# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Dear Fellow RenovoRx Shareholders,The first quarter of 2024 marked a significant period in our company's evolution, and we ...
Data shows that the Trans-Arterial Micro-Perfusion (TAMP) platform increases intra-arterial pressure, improving drug delivery w...
Cash position now expected to fund current operating plan into 2026Financing provides cash runway to advance the ongoing pivota...
Alliance Global Partners analyst Scott Henry initiates coverage on RenovoRx (NASDAQ:RNXT) with a Buy rating and announces Pr...
Shares of Longboard Pharmaceuticals, Inc.